Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
NCT04652518Phase 2Terminated
- Sponsor
- PureTech Health
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of deupirfenidone in post acute COVID-19 syndrome, sponsored by PureTech Health. Started Dec 2020; status: terminated.
02
Drugs
deupirfenidone
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT04652518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652518.